GSTO and AS3MT genetic polymorphisms and differences in urinary arsenic concentrations among residents in Bangladesh

References

• Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, Gamble MV, Graziano JH. (2007). Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev 16:1270–1278.
   PubMed Web of Science ®Google Scholar
• Breton CV, Zhou W, Kile ML, Houseman EA, Quamruzzaman Q, Rahman M, Mahiuddin G, Christiani DC. (2007). Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes. Carcinogenesis 28:1520–1525.
   PubMed Web of Science ®Google Scholar
• Challenger F. (1945). Biological methylation. Chemical Reviews 36, 315–361.
   Web of Science ®Google Scholar
• Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Chao SC, Lee JY, Christiani DC. (2003). Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248.
   PubMed Web of Science ®Google Scholar
• Fujihara J, Soejima M, Koda Y, Kunito T, Takeshita H. (2008). Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Mutat Res 654:158–161.
   PubMed Web of Science ®Google Scholar
• Hernández A, Xamena N, Sekaran C, Tokunaga H, Sampayo-Reyes A, Quinteros D, Creus A, Marcos R. (2008a). High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet Genomics 18:349–355.
   PubMed Web of Science ®Google Scholar
• Hernández A, Xamena N, Surrallés J, Sekaran C, Tokunaga H, Quinteros D, Creus A, Marcos R. (2008b). Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res 637:80–92.
   PubMed Web of Science ®Google Scholar
• Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ. (2002). Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83–91.
   PubMed Web of Science ®Google Scholar
• International Agency For Research on Cancer (IARC). (1980). Arsenic and Arsenic Compounds. Lyon: IARC monographs 23.
   Google Scholar
• Kile ML, Hoffman E, Hsueh YM, Afroz S, Quamruzzaman Q, Rahman M, Mahiuddin G, Ryan L, Christiani DC. (2009). Variability in biomarkers of arsenic exposure and metabolism in adults over time. Environ Health Perspect 117:455–460.
   PubMed Web of Science ®Google Scholar
• Lindberg AL, Ekström EC, Nermell B, Rahman M, Lönnerdal B, Persson LA, Vahter M. (2008). Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh. Environ Res 106:110–120.
   PubMed Web of Science ®Google Scholar
• Lindberg AL, Kumar R, Goessler W, Thirumaran R, Gurzau E, Koppova K, Rudnai P, Leonardi G, Fletcher T, Vahter M. (2007). Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ Health Perspect 115:1081–1086.
   PubMed Web of Science ®Google Scholar
• Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, Silbergeld EK. (2003). Variability in human metabolism of arsenic. Environ Res 92:85–91.
   PubMed Web of Science ®Google Scholar
• Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA, Walsh B, Avram MD, Kopplin MJ, Cebrián ME, Silbergeld EK, Aposhian HV. (2003). Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507–1513.
   PubMed Web of Science ®Google Scholar
• McCarty KM, Chen YC, Quamruzzaman Q, Rahman M, Mahiuddin G, Hsueh YM, Su L, Smith T, Ryan L, Christiani DC. (2007). Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ Health Perspect 115:341–345.
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Gaunt TR, Day IN. (2009). Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169:505–514.
   PubMed Web of Science ®Google Scholar
• Schmuck EM, Board PG, Whitbread AK, Tetlow N, Cavanaugh JA, Blackburn AC, Masoumi A. (2005). Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet Genomics 15:493–501.
   PubMed Web of Science ®Google Scholar
• Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH. (2005). Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924.
   PubMed Web of Science ®Google Scholar
• Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, Basu A, Porter KE, Hubbard A, Bates MN, Smith MT, Smith AH. (2010). Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol Appl Pharmacol 247:138–145.
   PubMed Web of Science ®Google Scholar
• Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ. (2000). Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289–299.
   PubMed Web of Science ®Google Scholar
• Tanaka-Kagawa T, Jinno H, Hasegawa T, Makino Y, Seko Y, Hanioka N, Ando M. (2003). Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem Biophys Res Commun 301:516–520.
   PubMed Web of Science ®Google Scholar
• Tseng CH. (2009). A review on environmental factors regulating arsenic methylation in humans. Toxicol Appl Pharmacol 235:338–350.
   PubMed Web of Science ®Google Scholar
• Vahter M. (1999). Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82 (Pt 1):69–88.
   PubMedGoogle Scholar
• Vahter M. (2002). Mechanisms of arsenic biotransformation. Toxicology 181–182:211–217.
   PubMed Web of Science ®Google Scholar
• Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. (2001). Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225–232.
   PubMed Web of Science ®Google Scholar
• Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. (2003). Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 13:131–144.
   PubMedGoogle Scholar
• Wood TC, Salavagionne OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. (2006). Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364–7373.
   PubMed Web of Science ®Google Scholar
• Yu RC, Hsu KH, Chen CJ, Froines JR. (2000). Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262.
   PubMed Web of Science ®Google Scholar
• Zakharyan RA, Aposhian HV. (1999). Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase. Chem Res Toxicol 12:1278–1283.
   PubMed Web of Science ®Google Scholar
• Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, Aposhian HV. (2001). Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol 14:1051–1057.
   PubMed Web of Science ®Google Scholar